Key result
Pre-PCI Impella is linked to improved one-year survival and ~89% less severe bleeding versus during/after PCI.
Why the study?
A better understanding of the safety, effectiveness, and timing of Impella initiation in specific clinical settings was needed.
Does pre-PCI Impella implantation improve survival compared to during/after PCI implantation in patients with cardiogenic shock or undergoing high-risk PCI?
Observational (n=365)
Yes
Does pre-PCI Impella implantation improve survival compared to during/after PCI implantation in patients with cardiogenic shock or undergoing high-risk PCI?
Initiating Impella mechanical circulatory support prior to PCI, rather than during or after the procedure, is associated with improved 1-year survival and lower bleeding risk in patients with AMI-cardiogenic shock or undergoing high-risk PCI.
Answers are grounded in this paper and cite their sources.
May support pre-PCI Impella in shock or high-risk PCI; leaves open randomized confirmation of survival benefit.
OBJECTIVE: To evaluate the role of the microaxial percutaneous mechanical circulatory support device (Impella® pump) implantation pre-percutaneous coronary intervention (PCI) versus during/after PCI in cardiogenic shock (CS) and high-risk PCI populations. BACKGROUND: A better understanding of the safety and effectiveness of the Impella and the role of timing of this support initiation in specific clinical settings is of utmost clinical relevance. METHODS: A total of 365 patients treated with Impella 2.5/CP in the 17 centers of the IMP-IT Registry were included. Through propensity-score weighting (PSW) analysis, 1-year clinical outcomes were assessed separately in CS and HR-PCI patients, stratified by timing of Impella support. RESULTS: Pre-procedural insertion was associated with an improvement in 1-year survival in patients with CS due to acute myocardial infarction (AMI) treated with PCI (p = .04 before PSW, p = .009 after PSW) and HR-PCI (p < .01 both before and after PSW). Among patients undergoing HR-PCI, early Impella support was also associated with a lower rate of the composite of mortality, re-hospitalization for heart failure, and need for left-ventricular assist device/heart transplantation at 1-year (p = .04 before PSW, p = .01 after PSW). Furthermore, Impella use during/after PCI was associated with an increased in-hospital life-threatening and severe bleeding among patients with AMI-CS receiving PCI (7 vs. 16%, p = .1) and HR-PCI (1 vs. 9%, p = .02). CONCLUSIONS: Our findings suggested a survival benefit and reduced rates of major bleeding when a pre-PCI Impella implantation instead of during-after procedure was used in the setting of HR-PCI and AMI-CS.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2021) conducted an observational in Cardiogenic shock and high-risk percutaneous coronary intervention (PCI) (n=365). Pre-PCI Impella implantation vs. Impella implantation during or after PCI was evaluated on 1-year survival (p=0.009). Pre-PCI Impella implantation improved 1-year survival in cardiogenic shock and reduced severe bleeding in high-risk PCI compared to during/after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: